Boosting subdominant neutralizing antibody responses with a computationally designed epitope-focused immunogen

PLoS Biol. 2019 Feb 21;17(2):e3000164. doi: 10.1371/journal.pbio.3000164. eCollection 2019 Feb.

Abstract

Throughout the last several decades, vaccination has been key to prevent and eradicate infectious diseases. However, many pathogens (e.g., respiratory syncytial virus [RSV], influenza, dengue, and others) have resisted vaccine development efforts, largely because of the failure to induce potent antibody responses targeting conserved epitopes. Deep profiling of human B cells often reveals potent neutralizing antibodies that emerge from natural infection, but these specificities are generally subdominant (i.e., are present in low titers). A major challenge for next-generation vaccines is to overcome established immunodominance hierarchies and focus antibody responses on crucial neutralization epitopes. Here, we show that a computationally designed epitope-focused immunogen presenting a single RSV neutralization epitope elicits superior epitope-specific responses compared to the viral fusion protein. In addition, the epitope-focused immunogen efficiently boosts antibodies targeting the palivizumab epitope, resulting in enhanced neutralization. Overall, we show that epitope-focused immunogens can boost subdominant neutralizing antibody responses in vivo and reshape established antibody hierarchies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal, Humanized / chemistry
  • Antibodies, Monoclonal, Humanized / immunology
  • Antibodies, Neutralizing / biosynthesis*
  • Antibodies, Neutralizing / genetics
  • Antibodies, Viral / biosynthesis*
  • Antibodies, Viral / genetics
  • Cloning, Molecular
  • Computer-Aided Design
  • Epitopes / chemistry*
  • Epitopes / immunology
  • Escherichia coli / genetics
  • Escherichia coli / metabolism
  • Female
  • Gene Expression
  • Genetic Vectors / chemistry
  • Genetic Vectors / metabolism
  • Immunization / methods
  • Immunogenicity, Vaccine
  • Mice
  • Mice, Inbred BALB C
  • Nanoparticles / administration & dosage
  • Nanoparticles / chemistry
  • Palivizumab / chemistry
  • Palivizumab / immunology
  • Receptors, Antigen, B-Cell / chemistry
  • Receptors, Antigen, B-Cell / genetics
  • Receptors, Antigen, B-Cell / immunology*
  • Recombinant Fusion Proteins / administration & dosage
  • Recombinant Fusion Proteins / chemistry*
  • Recombinant Fusion Proteins / genetics
  • Recombinant Fusion Proteins / immunology
  • Respiratory Syncytial Virus Vaccines / administration & dosage
  • Respiratory Syncytial Virus Vaccines / biosynthesis
  • Respiratory Syncytial Virus Vaccines / genetics
  • Respiratory Syncytial Viruses / immunology*
  • Structural Homology, Protein
  • Viral Fusion Proteins / administration & dosage
  • Viral Fusion Proteins / chemistry*
  • Viral Fusion Proteins / genetics
  • Viral Fusion Proteins / immunology

Substances

  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Epitopes
  • Receptors, Antigen, B-Cell
  • Recombinant Fusion Proteins
  • Respiratory Syncytial Virus Vaccines
  • Viral Fusion Proteins
  • motavizumab
  • Palivizumab

Grants and funding

FS was supported by the Swiss initiative for systems biology (SystemsX.ch). BEC was supported by the European Research Council (Starting grant - 716058) and the Swiss National Science Foundation (Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; 310030_163139). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.